Future of Diabetes...What next for Gliptins

Future of Diabetes...What next for Gliptins

Dipeptidyl peptidase-4 (DPP-4) inhibitors, or gliptins, are a relatively new class of oral drugs for type 2 diabetes. These drugs block the DPP-4 enzyme metabolism of incretin hormones, including GLP-1 and GIP. In this issue of Diabetes News Nucleus, let us understand more about gliptins and the future of diabetes management with special focus on this new class of drugs.

Dr. Sanjay Kalra

Dr. Sanjay Kalra is a DM (AIIMS) President-elect, SAFES Bharti Hospital, Karnal, India. MBBS, MD (Medicine), DM (Endocrinology), Practicing since 2000 Proprietor of Bharti Research Institute of Diabetes & Endocrinology (BRIDE), Karnal, Haryana. MBBS graduate from Punjab University (Chandigarh) with additional MD (Medicine) and DM (Endocrinology) qualifications from MDU (Rohtak) and AIIMS (New Delhi) respectively. Post-Graduate Diploma in Rural Development (PGDRD). An Executive Editor of the Indian Journal of Endocrinology & Metabolism and Editor-in-Chief of the International Journal of Clinical Cases & Investigations. Vice President of South Asian Federation of Endocrine Societies, since 2013. An international lecturer and author of numerous published peer-reviewed research papers and an active peer reviewer. His outstanding research background has earned him several national clinical awards.

 More FAQs by Dr. Sanjay Kalra

Get our Newsletter

Filter out the noise and nurture your inbox with health and wellness advice that's inclusive and rooted in medical expertise.

Your privacy is important to us




© 2022 Medtalks